A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

European Journal of Cancer

Volumn 31, Issue 2, 1995, Pages 261-267

  Handgretinger, R ^a   Anderson, K ^a   Lang, P ^a   Dopfer, R ^a   Klingebiel, T ^a   Schrappe, M ^a   Reuland, P ^a   Gillies, S D ^a   Reisfeld, R A ^a   Niethammer, D ^a  

^a NONE

Author keywords

chimeric MAb ch14.18; neuroblastoma; therapy

Indexed keywords

ANTIHISTAMINIC AGENT; CHIMERIC ANTIBODY; CORTICOSTEROID; GANGLIOSIDE GD2; GANGLIOSIDE GD2 ANTIBODY; MORPHINE; UNCLASSIFIED DRUG;

ADIE SYNDROME; ARTHRALGIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROBLASTOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; URTICARIA;

3-IODOBENZYLGUANIDINE; ANIMALS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; GANGLIOSIDES; HEMOLYSIS; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; MALE; MICE; NEUROBLASTOMA;

EID: 0028946423     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(94)00413-Y     Document Type: Article

References (24)

1. MIBG-treatment in neuroblastoma: experiences of the Tübingen/Frankfurt group
2. Bone marrow transplantation in children with neuroblastoma
3. Human tumor antigens
4. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody
5. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients
6. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal anti-ganglioside GD2 antibody 14.18
7. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma
8. Reassessment of patient response to monoclonal antibody 3F8
9. Phase I trial of the murine monoclonal anti-GD2 antibody 14.G2a in metastatic melanoma
10. A phase I trial of murine monoclonal antibody 14.G2a (anti-GD2) given by prolonged intravenous infusion in patients with neuroectodermal tumors
11. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a
12. Effect of a chimeric antiganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells
13. Effects of campath-1 antibody in vivo in patients with lymphoid malignancies: influence of antibody isotype
14. A proposed staging with neuroblastoma
15. High level expression of chimeric antibodies using adopted cDNA variable region cassettes
16. Human neuroblastoma cells in continuous culture: morphology and growth, tumorigenicity and cytogenetics of human neuroblastoma cells in continuous culture
17. Interferon-gamma up-regulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells
18. 131I-Iodobenzylguamidine
19. 131I]benzylguanidine (mIBG) in the diagnosis and follow-up of neuroblastoma
20. The value of determination of homoranillic and vanillylmandelic acids in plasma for the diagnosis and follow-up of neuroblastoma in children
21. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma
22. Gangliosides in normal human serum-concentration, pattern and transport by lipoproteins
23. Aggregation properties of gangliosides in aqueous solutions
24. Murine and chimeric antibodies to GD2 antigen in melanoma patients: pharmacokinetics and immune response